The Therapeutic Values of IL-7/IL-7R and the Recombinant Derivatives in Glioma: A Narrative Review.

IF 1.9 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Journal of Interferon and Cytokine Research Pub Date : 2023-08-01 DOI:10.1089/jir.2023.0050

Marjan Hesari, Zeinab Attar, Shakiba Soltani-Shirazi, Omid Keshavarzian, Reza Taheri, Reza Tabrizi, Hamed Fouladseresht

{"title":"The Therapeutic Values of IL-7/IL-7R and the Recombinant Derivatives in Glioma: A Narrative Review.","authors":"Marjan Hesari, Zeinab Attar, Shakiba Soltani-Shirazi, Omid Keshavarzian, Reza Taheri, Reza Tabrizi, Hamed Fouladseresht","doi":"10.1089/jir.2023.0050","DOIUrl":null,"url":null,"abstract":"<p><p>Interleukin-7 (IL-7) is essential for maintaining the immune system's defense functions by regulating the development and homeostasis of lymphocytes. Findings have shown the high efficacy of IL-7/IL-7 receptor (IL-7R)-based immunotherapy on various malignancies, with confirmation in both animal models and humans. In recent years, the progression-free survival and overall survival of patients suffering from gliomas significantly increased by introducing C7R-expressing chimeric antigen receptor (CAR)-T cells and long-acting IL-7 agonists such as NT-I7 (rhIL-7-hyFc, Efineptakin alfa). However, the effect of IL-7-based immunotherapies on the resistance of tumor cells to chemotherapy (when used simultaneously with chemotherapy agents) is still ambiguous and requires further studies. This article first reviews the pathophysiological roles of IL-7/IL-7R in tumors, focusing on gliomas. Subsequently, it discusses the therapeutic values of IL-7/IL-7R and the recombinant derivatives in gliomas.</p>","PeriodicalId":16261,"journal":{"name":"Journal of Interferon and Cytokine Research","volume":"43 8","pages":"319-334"},"PeriodicalIF":1.9000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Interferon and Cytokine Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jir.2023.0050","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Interleukin-7 (IL-7) is essential for maintaining the immune system's defense functions by regulating the development and homeostasis of lymphocytes. Findings have shown the high efficacy of IL-7/IL-7 receptor (IL-7R)-based immunotherapy on various malignancies, with confirmation in both animal models and humans. In recent years, the progression-free survival and overall survival of patients suffering from gliomas significantly increased by introducing C7R-expressing chimeric antigen receptor (CAR)-T cells and long-acting IL-7 agonists such as NT-I7 (rhIL-7-hyFc, Efineptakin alfa). However, the effect of IL-7-based immunotherapies on the resistance of tumor cells to chemotherapy (when used simultaneously with chemotherapy agents) is still ambiguous and requires further studies. This article first reviews the pathophysiological roles of IL-7/IL-7R in tumors, focusing on gliomas. Subsequently, it discusses the therapeutic values of IL-7/IL-7R and the recombinant derivatives in gliomas.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

IL-7/IL-7R及其重组衍生物在胶质瘤中的治疗价值

白细胞介素-7 (IL-7)通过调节淋巴细胞的发育和体内平衡，对维持免疫系统的防御功能至关重要。研究结果表明，基于IL-7/IL-7受体(IL-7R)的免疫治疗对多种恶性肿瘤具有很高的疗效，并在动物模型和人类中得到证实。近年来，通过引入表达c7r的嵌合抗原受体(CAR)-T细胞和长效IL-7激动剂如NT-I7 (rhIL-7-hyFc, Efineptakin alfa)，胶质瘤患者的无进展生存期和总生存期显著提高。然而，基于il -7的免疫疗法(与化疗药物同时使用时)对肿瘤细胞化疗耐药的影响仍然不明确，需要进一步研究。本文首先综述了IL-7/IL-7R在肿瘤中的病理生理作用，重点是胶质瘤。随后讨论了IL-7/IL-7R及其重组衍生物在胶质瘤中的治疗价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Interferon and Cytokine Research 医学-免疫学

CiteScore

3.80

自引率

0.00%

发文量

审稿时长

2.2 months

期刊介绍： Journal of Interferon & Cytokine Research (JICR) provides the latest groundbreaking research on all aspects of IFNs and cytokines. The Journal delivers current findings on emerging topics in this niche community, including the role of IFNs in the therapy of diseases such as multiple sclerosis, the understanding of the third class of IFNs, and the identification and function of IFN-inducible genes.